Cardiff Oncology Inc reports results for the quarter ended in June - Earnings Summary

Cardiff Oncology

05/08/2021 23:14

* Cardiff Oncology Inc  CRDF.OQ  reported a quarterly adjusted
loss of 17 cents​​ per share for the quarter ended in June. The
mean expectation of four analysts for the quarter was for a loss
of 15 cents per share.
* Revenue rose 59.5% to $68.00 thousand from a year ago; 
analysts expected $152.50 thousand. 
* Cardiff Oncology Inc's reported EPS for the quarter was a loss
of 17 cents​.
* The mean earnings estimate of analysts had risen by about 3.2%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Cardiff Oncology Inc shares had fallen by 24.7% this
quarter and lost 72.2% so far this year.
* The company reported a quarterly loss of $6.76 million.
* Wall Street's median 12-month price target for Cardiff
Oncology Inc is $25.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 5 at 10:14 p.m.  ​All
figures in US dollars unless otherwise stated